A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 14, 2016

Primary Completion Date

May 22, 2017

Study Completion Date

May 22, 2017

Conditions
Multiple Myeloma
Interventions
DRUG

Revlimid

Revlimid was used with dexamethasone to treat patients with multiple myeloma

DRUG

Velcade

Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma

DRUG

dexamethasone

Dexamethasone was a steroid used to treat patients with multiple myeloma.

DRUG

Farydak

FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.

Trial Locations (5)

30342

Northside Hospital Central Research Dept., Atlanta

33028

Memorial West Cancer Center Memorial Cancer Institute, Pembroke Pines

68124

Oncology Hematology West Nebraska Cancer Specialists dbaNebraska Cancer Specialists, Omaha

78234

Brooke Army Medical Center Hematology/Oncology, San Antonio

90095

David Geffen School of Medicine at UCLA UCLA, Los Angeles

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY